Tuberculin, purified protein derivative - Biologic Drug Details

Summary for tuberculin, purified protein derivative

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	3

Pharmacology for tuberculin, purified protein derivative

Physiological Effect	Cell-mediated Immunity
Established Pharmacologic Class	Skin Test Antigen Tuberculosis Skin Test
Chemical Structure	Antigens, Bacterial

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tuberculin, purified protein derivative Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tuberculin, purified protein derivative Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tuberculin, purified protein derivative Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Tuberculin Purified Protein Derivative (PPD)

Last updated: February 15, 2026

Overview

Tuberculin purified protein derivative (PPD) is a diagnostic agent used in tuberculosis (TB) testing. Despite its longstanding use, the market landscape and financial outlook are influenced by evolving TB epidemiology, diagnostic technology innovations, regulatory environments, and manufacturing trends.

Market Size and Growth Drivers

The global TB diagnostics market was valued at approximately USD 2.5 billion in 2022, with PPD-based skin tests comprising a significant segment [1]. The segment's growth is driven by TB prevalence, especially in high-burden countries such as India, Indonesia, and Nigeria, where PPD remains a primary screening tool.

In 2021, the World Health Organization (WHO) estimated 10 million new TB cases globally, with 1.5 million deaths [2]. This sustains demand for TB testing, indirectly supporting PPD utilization, despite technological shifts.

Manufacturing Dynamics

Major producers include Staten Serum Institut (SSI), RT Germany, and local suppliers in high-burden countries. Manufacturing faces challenges including:

• Standardization: Variability in PPD preparations impacts test reliability.
• Regulatory requirements: Stringent quality controls in the EU FDA and WHO prequalification standards.
• Supply chain issues: Especially during COVID-19 disruptions, leading to intermittent supply shortages.

There’s an increase in local manufacturing initiatives in endemic regions to improve supply security and reduce costs.

Technological Competition

Interferon-gamma release assays (IGRAs), such as QuantiFERON-TB Gold and T-SPOT.TB, are alternative diagnostics gaining adoption. IGRAs offer higher specificity, especially in BCG-vaccinated populations, and require less technical skill.

This shift impacts the PPD market by:

• Limiting use primarily to initial screening in resource-limited settings.
• Leading to a decline in PPD demand in wealthier countries adopting IGRAs.

Despite this, PPD remains the frontline test in many low-resource settings due to cost-effectiveness.

Regulatory and Policy Trends

• The WHO recommends both PPD skin tests and IGRAs, with the choice dependent on epidemiology and resource availability.
• Several countries incentivize Xpert MTB/RIF and IGRAs over skin testing, influencing market dynamics.
• Regulatory approvals for PPD are generally stable; however, quality control and batch-to-batch consistency are under increased scrutiny.

Economic Outlook

The PPD segment is expected to experience modest decline in high-income countries due to the shift to IGRAs but will remain stable or slightly grow in low- and middle-income countries (LMICs).

Market forecasts estimate a compound annual growth rate (CAGR) of approximately 1-2% through 2030 in LMICs, driven by ongoing TB burden and expansion of TB programs [3].

Margins for manufacturers are constrained:

• Fixed-cost manufacturing, pricing pressures, and competition reduce profit potential.
• Governments and NGOs often subsidize TB testing, affecting revenue streams.

Key Opportunities and Risks

Opportunities include:

• Developing standardized, more reliable PPD formulations.
• Expanding use in pediatric and HIV populations.
• Local manufacturing capacity building.

Risks involve:

• Adoption of IGRAs reducing PPD market share.
• Regulatory hurdles and quality concerns.
• Global efforts aimed at TB elimination potentially decreasing testing needs.

Summary Table

Factor	Impact	Details
Market size (2022)	USD 2.5 billion	Significant in LMICs
Growth rate (2022–2030)	1–2% CAGR in LMICs	Driven by TB burden expansion
Key competitors	IGRAs (QuantiFERON, T-SPOT)	Higher specificity, costlier
Manufacturing landscape	Limited global producers, local manufacturing in LMICs	Quality control varies, supply chain stability vital
Regulatory environment	Stable but rigorous, quality standards emphasized	Batch consistency crucial

Key Takeaways

• PPD retains importance primarily in resource-limited settings.
• Market growth is slow domestically but steady in LMICs owing to persistent TB burden.
• Competition from IGRAs limits global expansion prospects.
• Manufacturing focus centers on quality control and local capacity.
• Policy shifts favor advanced diagnostics, potentially diminishing PPD's role over time.

FAQs

1. What factors influence PPD demand in different regions?
   TB prevalence, screening policies, availability of alternative diagnostics, and health system infrastructure.

2. How does technological innovation affect PPD's market share?
   Introduction of IGRAs offers higher specificity but at increased costs, reducing PPD reliance especially in wealthier nations.

3. Are there ongoing efforts to improve PPD formulations?
   Yes, manufacturers and regulators seek standardized preparations to improve diagnostic accuracy and batch consistency.

4. What role does regulatory environment play in PPD market stability?
   Compliance with WHO, FDA, and local standards ensures continued supply but can impose barriers due to quality requirements.

5. What is the outlook for PPD in the next decade?
   Market stability persists mainly in LMICs; global decline expected as TB diagnostics evolve.

References

[1] MarketsandMarkets. "TB Diagnostics Market," 2022.
[2] WHO. "Global Tuberculosis Report," 2022.
[3] BCC Research. "Global TB Diagnostics Market Outlook," 2022.